AU2001295760A1 - Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders - Google Patents

Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders

Info

Publication number
AU2001295760A1
AU2001295760A1 AU2001295760A AU9576001A AU2001295760A1 AU 2001295760 A1 AU2001295760 A1 AU 2001295760A1 AU 2001295760 A AU2001295760 A AU 2001295760A AU 9576001 A AU9576001 A AU 9576001A AU 2001295760 A1 AU2001295760 A1 AU 2001295760A1
Authority
AU
Australia
Prior art keywords
resveratrol
treating inflammatory
respiratory disorders
inflammatory respiratory
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001295760A
Other languages
English (en)
Inventor
Peter John Barnes
Louise Elizabeth Donnelly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial College Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College Innovations Ltd filed Critical Imperial College Innovations Ltd
Publication of AU2001295760A1 publication Critical patent/AU2001295760A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001295760A 2000-10-19 2001-10-19 Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders Abandoned AU2001295760A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/694,108 2000-10-19
US09/694,108 US6878751B1 (en) 2000-10-19 2000-10-19 Administration of resveratrol to treat inflammatory respiratory disorders
PCT/GB2001/004672 WO2002032410A2 (en) 2000-10-19 2001-10-19 Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders

Publications (1)

Publication Number Publication Date
AU2001295760A1 true AU2001295760A1 (en) 2002-04-29

Family

ID=24787430

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001295760A Abandoned AU2001295760A1 (en) 2000-10-19 2001-10-19 Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders

Country Status (12)

Country Link
US (1) US6878751B1 (pt)
EP (1) EP1326595B1 (pt)
AT (1) ATE330589T1 (pt)
AU (1) AU2001295760A1 (pt)
CA (1) CA2425420C (pt)
CY (1) CY1107498T1 (pt)
DE (1) DE60121012T2 (pt)
DK (1) DK1326595T3 (pt)
ES (1) ES2266271T3 (pt)
PT (1) PT1326595E (pt)
WO (1) WO2002032410A2 (pt)
ZA (1) ZA200302727B (pt)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2419164T3 (es) 2001-11-02 2013-08-19 The Regents Of The University Of California Composiciones para la prevención y el tratamiento de una enfermedad inflamatoria, una enfermedad autoinmune, y rechazo de trasplante
US20070218152A1 (en) * 2002-03-12 2007-09-20 Roberto Moura Process for obtention of decoctions of Vitis labrusca and Vitis vinifera skins
ES2275778T3 (es) * 2002-06-06 2007-06-16 Chiesi Farmaceutici S.P.A. Solubilizacion de farmacos en propulsores de hfa mediante emulsiones.
EA200500012A1 (ru) * 2002-06-13 2006-04-28 Уайт Холдингз Корпорейшн Ингибиторы активности генов воспаления и биосинтеза холестерина
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
JP2006503865A (ja) * 2002-09-30 2006-02-02 アキュスフィア， インコーポレイテッド 吸入のための徐放性の多孔性微粒子
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
EP1644006A1 (en) * 2003-05-28 2006-04-12 Université de Liège Pharmaceutical composition for the treatment and/or the prevention of atherosclerosis from infectious origin
AU2004279644A1 (en) * 2003-10-10 2005-04-21 Resverlogix Corp. Treatment of diseases associated with the egr-1 enhancer element
CA2805795C (en) 2004-01-20 2016-11-08 Brigham Young University Novel sirtuin activating compounds and methods for making the same
JP5140416B2 (ja) * 2004-06-21 2013-02-06 ユニヴァーシティー オブ ミシシッピ 望ましい化学的官能基を有する抗がん及び抗原虫ジヒドロアーテミシニン及びジヒドロアーテミシテンダイマー
EP1859040A2 (en) * 2005-02-25 2007-11-28 Isis Pharmaceuticals, Inc. Compositions and their uses directed to il-4r alpha
WO2006102407A2 (en) 2005-03-23 2006-09-28 Children's Medical Center Corporation Orthotic device for preventing and/or correcting deformational posterior plagiocephaly
WO2006127987A2 (en) * 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20060293261A1 (en) * 2005-06-24 2006-12-28 Taisho Pharmaceutical Co., Ltd. Clarithromycin or a salt thereof for the treatment or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli
EP1898897A2 (en) * 2005-07-07 2008-03-19 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
JP2009510174A (ja) * 2005-10-03 2009-03-12 アイシス ファーマシューティカルズ， インコーポレーテッド ブデソニドおよびｉｌ−４受容体アルファを標的化するアンチセンスオリゴヌクレオチドを用いた併用療法
US20070148211A1 (en) * 2005-12-15 2007-06-28 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
WO2007076366A2 (en) * 2005-12-20 2007-07-05 Isis Pharmaceuticals, Inc Double stranded nucleic acid molecules targeted to il-4 receptor alpha
EP1962869B1 (en) * 2005-12-21 2013-03-20 SolAeroMed Inc. Treatment of respiratory diseases
TW200800180A (en) * 2006-03-06 2008-01-01 Wyeth Corp Liquid and semi-solid pharmaceutical formulations and processes
FR2898493B1 (fr) * 2006-03-16 2008-08-08 Af Consulting Compositions cosmetiques, pharmaceutiques, alimentaires et veterinaires dont l'action d'activation de genes de type sirtuin permet de retarder le vieillissement des mammiferes et ses effets nefastes
ES2344920T3 (es) * 2006-03-28 2010-09-09 Epitech Group S.R.L. Composicion farmaceutica para el tratamiento de patologias provocadas por la respuesta general del sistema inmutario.
US8524654B2 (en) * 2007-05-21 2013-09-03 The Uab Research Foundation Prolyl endopeptidase inhibitors for reducing or preventing neutrophilic inflammation
US20100210735A1 (en) * 2007-08-06 2010-08-19 University Of Florida Research Foundation, Inc. Modulating the Activity of Nuclear Receptors in Order to Treat Hypoxia-Related Disorders
US20090258850A1 (en) * 2007-08-21 2009-10-15 Frincke James M Stabilized therapeutic compositions and formulations
EP2247299A4 (en) * 2007-12-21 2012-06-06 Univ Rochester MOLECULAR TARGETS FOR THE TREATMENT OF INFLAMMATION
CA2711834C (en) 2008-01-11 2017-03-14 Reata Pharmaceuticals, Inc. Synthetic triterpenoids and methods of use in the treatment of disease
GB0801032D0 (en) * 2008-01-21 2008-02-27 Univ York Immune modulation
US8815936B2 (en) * 2008-03-03 2014-08-26 Nad Life Pty Ltd Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders
CA2721666C (en) 2008-04-18 2017-05-23 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
NZ588708A (en) 2008-04-18 2012-09-28 Reata Pharmaceuticals Inc 2-cyano steroid derivatives including an anti-inflammatory pharmacore
KR101713140B1 (ko) 2008-04-18 2017-03-08 리타 파마슈티컬스 잉크. Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
DK2276493T3 (da) 2008-04-18 2019-01-02 Reata Pharmaceuticals Inc Antioxidative inflammationsmodulatorer: oleanolsyrederivater med amino- og andre modifikationer ved c-17
US20090307669A1 (en) * 2008-06-06 2009-12-10 Garst Jr Gerald Blaine Memory management for closures
US8314137B2 (en) 2008-07-22 2012-11-20 Trustess Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
ES2362065B1 (es) * 2009-12-15 2012-05-18 Consejo Superior De Investigaciones Cient�?Ficas (Csic) Compuestos con actividad antiinflamatoria.
MX357596B (es) 2010-04-12 2018-07-16 Reata Pharmaceuticals Inc Método para tratar obesidad utilizando moduladores de inflamación con antioxidantes.
CN101791292A (zh) * 2010-04-13 2010-08-04 江庆澜 虎杖苷喷雾剂在作为哮喘治疗药物中的应用
US20120121730A1 (en) * 2010-10-07 2012-05-17 Trinity Laboratories, Inc. Pharmaceutical and nutraceutical compositions for treating respiratory disease and associated phlegm
WO2012083306A2 (en) 2010-12-17 2012-06-21 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
US10273205B2 (en) 2011-01-03 2019-04-30 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms
US9962361B2 (en) 2011-01-03 2018-05-08 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US11279674B2 (en) 2011-01-03 2022-03-22 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US10647668B2 (en) 2011-01-03 2020-05-12 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US10308599B2 (en) 2011-01-03 2019-06-04 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US11407713B2 (en) 2011-01-03 2022-08-09 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US8933119B2 (en) 2011-01-03 2015-01-13 The William M. Yarbrough Foundation Method for treating phytophotodermatitis
US8865765B2 (en) 2011-01-12 2014-10-21 The William M. Yarbrough Foundation Method for treating eczema
US9532969B2 (en) 2011-02-08 2017-01-03 The William M. Yarbrough Foundation Method for treating psoriasis
UY33946A (es) 2011-03-11 2012-08-31 Reata Pharmaceuticals Inc Derivados de c4-monometil triterpenoides y sus métodos de uso
PL3444261T3 (pl) 2012-04-27 2021-07-19 Reata Pharmaceuticals, Inc. Pochodne 2,2-difluoropropionamidowe bardoksolonu metylu, ich kompozycje farmaceutyczne i formy polimorficzne do zastosowania w leczeniu określonych stanów
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9839621B2 (en) 2012-07-26 2017-12-12 The William M. Yarbrough Foundation Method for treating bladder cancer
WO2014018874A1 (en) 2012-07-26 2014-01-30 The William M. Yarbrough Foundation Method for treating skin cancer
US10080734B2 (en) 2012-07-26 2018-09-25 The William M. Yarbrough Foundation Method for treating autism and other neurodevelopmental disorders
US10335387B2 (en) 2012-07-26 2019-07-02 The William M. Yarbrough Foundation Method for treating infectious diseases with isothiocyanate functional compounds
US10434082B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
US9949943B2 (en) 2012-07-26 2018-04-24 The William M. Yarbrough Foundation Method for treating neurodegenerative diseases
US10434081B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Inhibitors of macrophage migration inhibitory factor
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
DK2892912T3 (da) 2012-09-10 2019-06-24 Reata Pharmaceuticals Inc C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf
AU2014207707B2 (en) 2013-01-15 2018-11-01 Nusirt Sciences, Inc. Treating pulmonary conditions
US9855223B2 (en) 2013-08-21 2018-01-02 Concordia University Compositions comprising a dendrimer-resveratrol complex and methods for making and using the same
US10667627B2 (en) 2015-05-05 2020-06-02 Children's Medical Center Corporation Devices and methods for supporting and containing premature babies and small-for-age infants
CA2998681C (en) 2015-09-23 2024-02-06 Reata Pharmaceuticals, Inc. C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
ES2673942B1 (es) * 2016-11-23 2019-04-09 Consejo Superior Investigacion Compuestos acilados para el tratamiento de patologias oculares
US12060340B2 (en) 2018-06-20 2024-08-13 Reata Pharmaceuticals, Inc Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith
EP4019013A1 (en) 2020-12-24 2022-06-29 Bionotus GCV Treatment of pulmonary disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1577196A (en) * 1977-06-03 1980-10-22 Ile De France Compositions containing erythromycin and metoclopramide
GB9218027D0 (en) * 1992-08-25 1992-10-14 Fisons Plc Novel method of treatment
US5411986A (en) 1993-03-12 1995-05-02 The Johns Hopkins University Chemoprotective isothiocyanates
IT1276225B1 (it) 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US5972995A (en) 1997-10-16 1999-10-26 Children's Hospital Medical Center Of Northern California Compositions and methods for cystic fibrosis therapy
US6414037B1 (en) 1998-01-09 2002-07-02 Pharmascience Pharmaceutical formulations of resveratrol and methods of use thereof
US6022901A (en) 1998-05-13 2000-02-08 Pharmascience Inc. Administration of resveratrol to prevent or treat restenosis following coronary intervention
WO2000013685A1 (en) 1998-09-08 2000-03-16 Cornell Research Foundation, Inc. Treating inflammatory diseases of the head and neck with cyclooxygenase-2 inhibitors
EP1140050B1 (en) 1998-12-24 2003-12-03 1333366 Ontario Inc. A composition useful to treat periodontal disease
PE20010540A1 (es) 1999-07-30 2001-05-15 Procter & Gamble Composicion de fitoalexinas estilbenicas util para la profilaxis y tratamiento de sintomas asociados con el resfriado y enfermedades similares a la influenza
IT1318425B1 (it) 2000-03-24 2003-08-25 D B P Dev Biotechnological Pro Impiego del resveratrolo per il trattamento di eczema desquamativo,acne e psoriasi.

Also Published As

Publication number Publication date
PT1326595E (pt) 2006-09-29
ZA200302727B (en) 2004-04-08
WO2002032410A3 (en) 2002-08-01
DK1326595T3 (da) 2006-10-23
CA2425420C (en) 2010-10-12
EP1326595A2 (en) 2003-07-16
DE60121012T2 (de) 2007-01-04
EP1326595B1 (en) 2006-06-21
CA2425420A1 (en) 2002-04-25
ES2266271T3 (es) 2007-03-01
ATE330589T1 (de) 2006-07-15
WO2002032410A2 (en) 2002-04-25
DE60121012D1 (de) 2006-08-03
CY1107498T1 (el) 2013-03-13
US6878751B1 (en) 2005-04-12

Similar Documents

Publication Publication Date Title
AU2001295760A1 (en) Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders
EP3494995A3 (en) Formoterol superfine formulation
BR0008699A (pt) Combinações de formoterol e furoato demometasona para asma
CA2409665A1 (en) Novel composition
MY126768A (en) Combinations of formoterol and fluticasone propionate for asthma
IL219785A (en) A process for preparing a pharmaceutical preparation containing an active ingredient and a micronized carrier / solvent
CA2550841A1 (en) Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases
RS52940B (en) PHARMACEUTICAL FORMULATIONS OF SOLUTION FOR MEASURED DOSES OF PRESSURE INHALATORS
CA2389349A1 (en) Aerosol composition comprising formoterol
FI20002215A0 (fi) Yhdistelmäpartikkelit
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
CA2474479A1 (en) Composition for inhalation
DK1341542T3 (da) Indanylderivater til behandling af luftvejssygdomme
PL350583A1 (en) Combinations of formoterol and a tiotropium salt
WO2005044187A3 (en) Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
AR039409A1 (es) Composicion farmaceutica en polvo seco para inhalacion, fabricacion y uso.
NZ547276A (en) Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
HK1078795A1 (en) Powder formulations suitable for inhalation
WO2005011604A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
IS2576B (is) Samverkandi samsetning sem felur í sér róflúmílast og (R.R)-formóteról
WO2005011602A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
WO2005011616A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
MXPA04007294A (es) Composicion para inhalacion.
WO2007046113A3 (en) Novel pharmaceutical composition comprising alkaloid and process thereof
WO2005011615A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease